A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

What is the Purpose of this Study?

This study focuses on people who have either advanced colorectal cancer or advanced pancreatic cancer that is driven by a gene known as RAS. The purpose of the study is to evaluate the safety of an investigational drug called RMC-9805 in combination with chemotherapy medicines, with or without another experimental drug called RMC-6236. The study will test RMC-9805 and RMC-6236 at different doses with a fixed, standard dose of combination anti-cancer therapy. Study procedures include physical exams, questionnaires, collection of blood and urine samples, echocardiogram, electrocardiograms, computed tomography scans, biopsies, and administration of study drugs.

Eligibility

All Patients (unless otherwise noted):
* ≥ 18 years of age
* ECOG PS is 0 to 1

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Abrahm Levi

More about this Clinical Trial

What is the full name of this clinical trial?

RMC-GI-102: Study of RAS Inhibitors in Patients with Advanced Gastrointestinal Solid Tumors

Study Details

Disease Type/Condition

Colon, Other Digestive Organ, Pancreas, Rectum

Principal Investigator

Osipov, Arsen

Co-Investigators

Andrew Hendifar, Emily Kaymen, Jun Gong, Kamya Sankar

Age Group

Adult

Phase

I/II

IRB Number

STUDY00004041

ClinicalTrials.gov ID

NCT06445062

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

Name

Abrahm Levi

Email

Abrahm.Levi@cshs.org

Study Detail